A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis."
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
Price : $35 *
At a glance
- Drugs Pirfenidone (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms PIRFENIVAS
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 04 Jan 2018 New trial record